Breaking News

Financial Report: Johnson & Johnson 1Q

April 16, 2014

Revenues up 3% in the quarter

Johnson & Johnson

1Q Revenues: $18.1 billion (+4%)

1Q Earnings: $4.7 billion (+35%)

Comments: Worldwide pharmaceutical sales were $7.5 billion, up 11%, driven by STELARA, INVEGA, SUSTENNA/XEPLION, PREZISTA, and VELCADE, as well as new products OLYSIO/SOVRIAD, a combination treatment of chronic hepatitis C, and ZYTIGA for the treatment of prostate cancer. Results were negatively impacted by loss of exclusivity for ACIPHEX and CONCERTA. In the quarter, the FDA approved IMBRUVICA capsules for the treatment of chronic lymphocytic leukemia, and the European Commission granted conditional approval for SIRTURO as part of a combination regimen for pulmonary multi-drug resistant tuberculosis. R&D expenses were $1.8 billion, up 3%.

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks